Phio Pharmaceuticals Corp. PHIO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · phiopharma.com
Phio Pharmaceuticals Corp. is a King of Prussia, Pennsylvania clinical-stage biopharmaceutical company developing siRNA cancer therapeutics with its proprietary INTASYL gene-silencing technology. Its lead candidate, PH-762, silences the PD-1 gene and has been evaluated in a Phase 1b trial as a non-surgical treatment for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.